Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 1
1970 1
1973 1
1980 1
1982 2
1984 3
1986 2
1987 1
1988 1
1993 2
1994 1
1995 1
1996 3
1997 10
1998 10
1999 13
2000 29
2001 34
2002 50
2003 59
2004 82
2005 95
2006 114
2007 99
2008 141
2009 144
2010 210
2011 268
2012 326
2013 393
2014 484
2015 547
2016 525
2017 576
2018 584
2019 602
2020 689
2021 725
2022 708
2023 665
2024 633
2025 232

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8,071 results

Results by year

Filters applied: . Clear all
Page 1
Metformin's impact on delirium in diabetic cardio surgery patients.
Lu Z, Sun M, Chen WM, Lv S, Fu N, Yang Y, Wang Y, Miao M, Wu SY, Zhang J. Lu Z, et al. J Anesth. 2025 Apr 26. doi: 10.1007/s00540-025-03504-y. Online ahead of print. J Anesth. 2025. PMID: 40285872
PURPOSE: The effect of metformin on postoperative delirium (POD) in patients with type 2 diabetes mellitus (T2DM) undergoing cardiovascular surgery remains unclear. ...These findings highlight metformin's potential as a chemopreventive agent against post-surg …
PURPOSE: The effect of metformin on postoperative delirium (POD) in patients with type 2 diabetes mellitus (T2DM) undergoing cardiova …
Mitigating Diabetic Cardiomyopathy: The Synergistic Potential of Sea Buckthorn and Metformin Explored via Bioinformatics and Chemoinformatics.
Safavi K, Abedpoor N, Hajibabaie F, Kaviani E. Safavi K, et al. Biology (Basel). 2025 Mar 31;14(4):361. doi: 10.3390/biology14040361. Biology (Basel). 2025. PMID: 40282226 Free article.
This study investigated the synergistic therapeutic potential of Hippophae rhamnoides L. (sea buckthorn, SBU) extract and metformin in a mouse model of T2DM-induced DCM. T2DM was induced using a 45% high-fat-AGEs-enriched diet, followed by treatment with SBU, metformin …
This study investigated the synergistic therapeutic potential of Hippophae rhamnoides L. (sea buckthorn, SBU) extract and metformin i …
Targeted inhibition of JMJD2C/MALAT1 axis compensates for the deficiency of metformin in reversing ovarian cancer platinum resistance.
Li L, Zhang J, Li H, Qin L, Wu H, Li Z, Cai L, Chen D, Yang J, Chen Y, Xie Y. Li L, et al. Life Sci. 2025 Apr 23:123663. doi: 10.1016/j.lfs.2025.123663. Online ahead of print. Life Sci. 2025. PMID: 40280301
AIMS: We explored JMJD2C's role in platinum resistance in ovarian cancer and its modulation by metformin to propose strategies for overcoming treatment limitations. ...SIGNIFICANCE: JMJD2C drives PR in OC by demethylating the MALAT1 promoter. Metformin upregu …
AIMS: We explored JMJD2C's role in platinum resistance in ovarian cancer and its modulation by metformin to propose strategies …
Metformin Inhibits Cell Motility and Proliferation of Triple-Negative Breast Cancer Cells by Blocking HMGB1/RAGE Signaling.
Yusein-Myashkova S, Vladimirova D, Gospodinov A, Ugrinova I, Todorova J. Yusein-Myashkova S, et al. Cells. 2025 Apr 13;14(8):590. doi: 10.3390/cells14080590. Cells. 2025. PMID: 40277915 Free PMC article.
This study investigates metformin's effects on the HMGB1/RAGE signaling pathway in triple-negative breast cancer (TNBC) cells. ...These findings highlight metformin's potential as a therapeutic agent in TNBC by inhibiting HMGB1/RAGE-driven metas …
This study investigates metformin's effects on the HMGB1/RAGE signaling pathway in triple-negative breast cancer (TNBC) …
Increased Risk of Cancer-An Integral Component of the Cardio-Renal-Metabolic Disease Cluster and Its Management.
Standl E, Schnell O. Standl E, et al. Cells. 2025 Apr 9;14(8):564. doi: 10.3390/cells14080564. Cells. 2025. PMID: 40277890 Free PMC article. Review.
Cancer risk increases by 25 to 250% not only in dysmetabolic obese or overweight people with overt type 2 diabetes but also in individuals with intermediate hyperglycemia (pre-diabetes), with especially pronounced risk of pancreatic or hepatocellular cancer and obes …
Cancer risk increases by 25 to 250% not only in dysmetabolic obese or overweight people with overt type 2 diabetes but also in indivi …
Comparative study of SGLT2 inhibitors and metformin: evaluating first-line therapies for dementia prevention in type 2 diabetes.
Sun M, Wang X, Lu Z, Yang Y, Lv S, Miao M, Chen WM, Wu SY, Zhang J. Sun M, et al. Diabetes Metab. 2025 Apr 21:101655. doi: 10.1016/j.diabet.2025.101655. Online ahead of print. Diabetes Metab. 2025. PMID: 40268162
Sodium-glucose cotransporter 2 inhibitors (SGLT2is) and metformin, widely used antidiabetic therapies, have demonstrated potential neuroprotective effects. ...CONCLUSIONS: - SGLT2is significantly reduced dementia risk and mortality compared to metformin in T2D patie …
Sodium-glucose cotransporter 2 inhibitors (SGLT2is) and metformin, widely used antidiabetic therapies, have demonstrated potential ne …
Metformin Enhances the Chemosensitivity of Gastric Cancer to Cisplatin by Downregulating Nrf2 Level.
Duan G, Qi M, Xun L, An Y, Zuo Z, Luo Y, Song Z. Duan G, et al. Anal Cell Pathol (Amst). 2025 Apr 15;2025:5714423. doi: 10.1155/ancp/5714423. eCollection 2025. Anal Cell Pathol (Amst). 2025. PMID: 40264514 Free PMC article.
Cisplatin-based chemotherapy resistance is a common issue for cancer clinical efficacy. Metformin is being studied for its possible anticancer effect. The present study aimed to investigate whether metformin affects the chemosensitivity of gastric cancer …
Cisplatin-based chemotherapy resistance is a common issue for cancer clinical efficacy. Metformin is being studied for its pos …
SDCBP/Syntenin-1 stabilizes BACH1 by disassembling the SCF(FBXO22)-BACH1 complex in triple-negative breast cancer.
Tran PL, Kim O, Hwangbo C, Kim HJ, Kim YM, Lee JH. Tran PL, et al. EMBO J. 2025 Apr 22. doi: 10.1038/s44318-025-00440-1. Online ahead of print. EMBO J. 2025. PMID: 40263598 Free article.
BACH1 is a redox-sensitive transcription factor facilitating tumor progression in triple-negative breast cancer (TNBC). However, the molecular mechanisms regulating BACH1 function in TNBC remain unclear. ...Moreover, depleting SDCBP leads to upregulation of BACH1-repressed …
BACH1 is a redox-sensitive transcription factor facilitating tumor progression in triple-negative breast cancer (TNBC). However, the …
Senotherapeutic repurposing of metformin for age-related diseases and their signaling pathways.
Turgut Ş, Atasever E, Cebe T, Andican G, Çakatay U. Turgut Ş, et al. Mol Biol Rep. 2025 Apr 22;52(1):410. doi: 10.1007/s11033-025-10524-0. Mol Biol Rep. 2025. PMID: 40261556 Review.
All these limitations indicate that further clinical research is required to determine the effectiveness of repurposed senotherapeutic drug interventions, such as metformin, for age-related diseases. Metformin exerts diverse senotherapeutic effects on various aging …
All these limitations indicate that further clinical research is required to determine the effectiveness of repurposed senotherapeutic drug …
8,071 results

Searches related to "metformin cancer"